Literature DB >> 24802033

Selection via pluripotency-related transcriptional screen minimizes the influence of somatic origin on iPSC differentiation propensity.

Katherine A Hartjes1, Xing Li, Almudena Martinez-Fernandez, Alexa J Roemmich, Brandon T Larsen, Andre Terzic, Timothy J Nelson.   

Abstract

The value of induced pluripotent stem cells (iPSCs) within regenerative medicine is contingent on predictable and consistent iPSC differentiation. However, residual influence of the somatic origin or reprogramming technique may variegate differentiation propensity and confound comparative genotype/phenotype analyses. The objective of this study was to define quality control measures to select iPSC clones that minimize the influence of somatic origin on differentiation propensity independent of the reprogramming strategy. More than 60 murine iPSC lines were derived from different fibroblast origins (embryonic, cardiac, and tail tip) via lentiviral integration and doxycycline-induced transgene expression. Despite apparent equivalency according to established iPSC histologic and cytomorphologic criteria, clustering of clonal variability in pluripotency-related gene expression identified transcriptional outliers that highlighted cell lines with unpredictable cardiogenic propensity. Following selection according to a standardized gene expression profile calibrated by embryonic stem cells, the influence of somatic origin on iPSC methylation and transcriptional patterns was negated. Furthermore, doxycycline-induced iPSCs consistently demonstrated earlier differentiation than lentiviral-reprogrammed lines using contractile cardiac tissue as a measure of functional differentiation. Moreover, delayed cardiac differentiation was predominately associated with upregulation in pluripotency-related gene expression upon differentiation. Starting from a standardized pool of iPSCs, relative expression levels of two pluripotency genes, Oct4 and Zfp42, statistically correlated with enhanced cardiogenicity independent of somatic origin or reprogramming strategy (R(2)  = 0.85). These studies demonstrate that predictable iPSC differentiation is independent of somatic origin with standardized gene expression selection criteria, while the residual impact of reprogramming strategy greatly influences predictable output of tissue-specification required for comparative genotype/phenotype analyses.
© 2014 AlphaMed Press.

Entities:  

Keywords:  Cardiac differentiation; Induced pluripotent stem cells; Transcriptional profile

Mesh:

Year:  2014        PMID: 24802033      PMCID: PMC4167634          DOI: 10.1002/stem.1734

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  51 in total

1.  c-MYC independent nuclear reprogramming favors cardiogenic potential of induced pluripotent stem cells.

Authors:  Almudena Martinez-Fernandez; Timothy J Nelson; Yasuhiro Ikeda; Andre Terzic
Journal:  J Cardiovasc Transl Res       Date:  2010-02       Impact factor: 4.132

2.  Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors.

Authors:  Hiroshi Ban; Naoki Nishishita; Noemi Fusaki; Toshiaki Tabata; Koichi Saeki; Masayuki Shikamura; Nozomi Takada; Makoto Inoue; Mamoru Hasegawa; Shin Kawamata; Shin-Ichi Nishikawa
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-05       Impact factor: 11.205

Review 3.  Induced pluripotent stem cells as a new strategy for cardiac regeneration and disease modeling.

Authors:  Olalla Iglesias-García; Beatriz Pelacho; Felipe Prósper
Journal:  J Mol Cell Cardiol       Date:  2013-04-30       Impact factor: 5.000

4.  Cell line-dependent differentiation of induced pluripotent stem cells into cardiomyocytes in mice.

Authors:  Shinji Kaichi; Koji Hasegawa; Tomohide Takaya; Noritaka Yokoo; Takahiro Mima; Teruhisa Kawamura; Tatsuya Morimoto; Koh Ono; Shiro Baba; Hiraku Doi; Shinya Yamanaka; Tatsutoshi Nakahata; Toshio Heike
Journal:  Cardiovasc Res       Date:  2010-06-14       Impact factor: 10.787

5.  Induced pluripotent stem cells generated without viral integration.

Authors:  Matthias Stadtfeld; Masaki Nagaya; Jochen Utikal; Gordon Weir; Konrad Hochedlinger
Journal:  Science       Date:  2008-09-25       Impact factor: 47.728

6.  iPS programmed without c-MYC yield proficient cardiogenesis for functional heart chimerism.

Authors:  Almudena Martinez-Fernandez; Timothy J Nelson; Satsuki Yamada; Santiago Reyes; Alexey E Alekseev; Carmen Perez-Terzic; Yasuhiro Ikeda; Andre Terzic
Journal:  Circ Res       Date:  2009-08-20       Impact factor: 17.367

Review 7.  Induced pluripotent stem cell-derived cardiomyocytes: a versatile tool for arrhythmia research.

Authors:  Daniel Sinnecker; Alexander Goedel; Karl-Ludwig Laugwitz; Alessandra Moretti
Journal:  Circ Res       Date:  2013-03-15       Impact factor: 17.367

8.  Genetically matched human iPS cells reveal that propensity for cartilage and bone differentiation differs with clones, not cell type of origin.

Authors:  Akira Nasu; Makoto Ikeya; Takuya Yamamoto; Akira Watanabe; Yonghui Jin; Yoshihisa Matsumoto; Kazuo Hayakawa; Naoki Amano; Shingo Sato; Kenji Osafune; Tomoki Aoyama; Takashi Nakamura; Tomohisa Kato; Junya Toguchida
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

9.  Prospective in vitro models of channelopathies and cardiomyopathies.

Authors:  Nanako Kawaguchi; Emiko Hayama; Yoshiyuki Furutani; Toshio Nakanishi
Journal:  Stem Cells Int       Date:  2012-03-27       Impact factor: 5.443

10.  piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells.

Authors:  Knut Woltjen; Iacovos P Michael; Paria Mohseni; Ridham Desai; Maria Mileikovsky; Riikka Hämäläinen; Rebecca Cowling; Wei Wang; Pentao Liu; Marina Gertsenstein; Keisuke Kaji; Hoon-Ki Sung; Andras Nagy
Journal:  Nature       Date:  2009-03-01       Impact factor: 49.962

View more
  8 in total

Review 1.  Induced pluripotent stem cells for cardiovascular disease: from product-focused disease modeling to process-focused disease discovery.

Authors:  Katherine A Campbell; Andre Terzic; Timothy J Nelson
Journal:  Regen Med       Date:  2015-10-06       Impact factor: 3.806

2.  Structural phenotyping of stem cell-derived cardiomyocytes.

Authors:  Francesco Silvio Pasqualini; Sean Paul Sheehy; Ashutosh Agarwal; Yvonne Aratyn-Schaus; Kevin Kit Parker
Journal:  Stem Cell Reports       Date:  2015-02-26       Impact factor: 7.765

3.  In Pursuit of Authenticity: Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Clinical Applications.

Authors:  Kiyoharu J Miyagishima; Qin Wan; Barbara Corneo; Ruchi Sharma; Mostafa R Lotfi; Nathan C Boles; Fang Hua; Arvydas Maminishkis; Congxiao Zhang; Timothy Blenkinsop; Vladimir Khristov; Balendu S Jha; Omar S Memon; Sunita D'Souza; Sally Temple; Sheldon S Miller; Kapil Bharti
Journal:  Stem Cells Transl Med       Date:  2016-07-11       Impact factor: 6.940

Review 4.  Stem Cell Therapies for Treatment of Liver Disease.

Authors:  Clara Nicolas; Yujia Wang; Jennifer Luebke-Wheeler; Scott L Nyberg
Journal:  Biomedicines       Date:  2016-01-06

Review 5.  Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come?

Authors:  Luca Sala; Milena Bellin; Christine L Mummery
Journal:  Br J Pharmacol       Date:  2016-09-20       Impact factor: 8.739

6.  CXCL4/PF4 is a predictive biomarker of cardiac differentiation potential of human induced pluripotent stem cells.

Authors:  Fumiya Ohashi; Shigeru Miyagawa; Satoshi Yasuda; Takumi Miura; Takuya Kuroda; Masayoshi Itoh; Hideya Kawaji; Emiko Ito; Shohei Yoshida; Atsuhiro Saito; Tadashi Sameshima; Jun Kawai; Yoshiki Sawa; Yoji Sato
Journal:  Sci Rep       Date:  2019-03-15       Impact factor: 4.379

7.  Quantification of Etoposide Hypersensitivity: A Sensitive, Functional Method for Assessing Pluripotent Stem Cell Quality.

Authors:  Frank J Secreto; Xing Li; Alyson J Smith; Elizabeth S Bruinsma; Ester Perales-Clemente; Saji Oommen; Gresin Hawse; Sybil C L Hrstka; Bonnie K Arendt; Emma B Brandt; Dennis A Wigle; Timothy J Nelson
Journal:  Stem Cells Transl Med       Date:  2017-09-19       Impact factor: 6.940

Review 8.  Opportunities and Limitations of Modelling Alzheimer's Disease with Induced Pluripotent Stem Cells.

Authors:  Dmitry A Ovchinnikov; Ernst J Wolvetang
Journal:  J Clin Med       Date:  2014-12-05       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.